青蒿素类药物的广谱性及其潜在作用机制的探讨

doi:10.12140/j.issn.1000-7423.2022.01.018

中国寄生虫学与寄生虫病杂志 ›› 2022, Vol. 40 ›› Issue (1): 114-120.doi: 10.12140/j.issn.1000-7423.2022.01.018

青蒿素类药物的广谱性及其潜在作用机制的探讨

刘闯¹(), 司雯雯², 张尹², 刘蓉², 刘毅², 欧阳瑞镯¹, 孙军²^,^*()

1 上海理工大学健康科学与工程学院,上海 200093
2 同济大学医学院,传染病与疫苗研究所,上海 200092

收稿日期:2021-07-24 修回日期:2021-09-07 出版日期:2022-02-28 发布日期:2022-01-14
通讯作者: 孙军
作者简介:刘闯（1994-）,女,硕士研究生,从事青蒿素抗疟机制研究。E-mail： chuang194@126.com
基金资助:
上海市教育委员会科研创新计划项目(201901070007E00017)

A discussion on the broad-spectrum and potential mechanism of artemisinin and its derivatives

LIU Chuang¹(), SI Wen-wen², ZHANG Yin², LIU Rong², LIU Yi², OUYANG Rui-zhuo¹, SUN Jun²^,^*()

1 School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China
2 Institute for Infectious Diseases and Vaccine Development, School of Medicine, Tongji University, Shanghai 200092, China

Received:2021-07-24 Revised:2021-09-07 Online:2022-02-28 Published:2022-01-14
Contact: SUN Jun
Supported by:
Innovation Program of Shanghai Municipal Education Commission(201901070007E00017)

摘要/Abstract

摘要：

青蒿素类药物不仅在治疗疟疾和血吸虫病方面具有独特的疗效,而且在其他疾病的治疗和防治中也具有潜力。越来越多的研究表明,青蒿素及其衍生物具有广泛的功能,这种广谱性正越来越引起人们的重视。本文综述了青蒿素类药物在寄生原虫、寄生蠕虫、病毒、细菌、真菌、昆虫、植物以及癌症疾病中应用的研究成果,并基于其作用的广谱性特征,结合青蒿素通过铁或血红素实现抗疟原虫、抗血吸虫、抗肿瘤效果的作用方式,探讨青蒿素广泛功能背后的潜在作用机制。

关键词: 青蒿素, 青蒿素衍生物, 作用机制

Abstract:

Artemisinin and its derivatives have unique efficacies in treating of malaria and schistosomiasis, and have potential in the treatment and prevention of other diseases. Increasing evidences have shown that artemisinin and its derivatives have sophisticated functions, and their broad-spectrum characteristics are attracting attention. This article summarizes the existing research on the application of artemisinin class drugs in parasitic protozoa, and parasitic worms, viruses, bacteria, fungi, insects, plants, and other diseases such as cancer and discusses the potential mechanisms behind the broad functions of artemisinin and its derivatives, based on the broad spectrum characteristics of artemisinin class drugs, and their antimalarial, anti-schistosomiasis and antitumor activities through iron or heme.

Key words: Artemisinin, Artemisinin derivatives, Mechanism

中图分类号:

R531

刘闯, 司雯雯, 张尹, 刘蓉, 刘毅, 欧阳瑞镯, 孙军. 青蒿素类药物的广谱性及其潜在作用机制的探讨[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(1): 114-120.

LIU Chuang, SI Wen-wen, ZHANG Yin, LIU Rong, LIU Yi, OUYANG Rui-zhuo, SUN Jun. A discussion on the broad-spectrum and potential mechanism of artemisinin and its derivatives[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2022, 40(1): 114-120.

图/表 3

图1

图2

图3

参考文献 58

[1]	Wang JG, Zhu YP, Xu CC, et al. Research course and value of artemisinin[J]. Elect J Emerg Infect Dis, 2019, 4(4): 193-195. (in Chinese)
[1]	(王继刚, 朱永平, 徐承超, 等. 青蒿素的研究历程与价值[J]. 新发传染病电子杂志, 2019, 4(4): 193-195.)
[2]	Sun C, Li J, Zhou B. Mechanism of action of artemisinins: a long unsettled challenge[J]. Sci China Life Sci, 2012, 42(5): 345-354. (in Chinese)
[2]	(孙辰, 李坚, 周兵. 青蒿素类药物的作用机制:一个长久未决的基础研究挑战[J]. 中国科学: 生命科学, 2012, 42(5): 345-354.)
[3]	Xiao SH. Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins[J]. Acta Trop, 2005, 96(2-3): 153-167.
[4]	Loo CS, Lam NS, Yu D, et al. Artemisinin and its derivatives in treating protozoan infections beyond malaria[J]. Pharmacol Res, 2017, 117: 192-217.
[5]	Lam NS, Long X, Su XZ, et al. Artemisinin and its derivatives in treating helminthic infections beyond schistosomiasis[J]. Pharmacol Res, 2018, 133: 77-100.
[6]	Efferth T, Romero MR, Wolf DG, et al. The antiviral activities of artemisinin and artesunate[J]. Clin Infect Dis, 2008, 47(6): 804-811.
[7]	Huang M, Shen JY, Du CC, et al. Preliminary study on antibacterial activity of artemisinin and its derivatives[J]. Chin J Chin Mater Med, 2019, 44(9): 1946-1952. (in Chinese)
[7]	(黄梅, 沈建英, 杜成成, 等. 青蒿素及其衍生物的抗菌活性初步研究[J]. 中国中药杂志, 2019, 44(9): 1946-1952.)
[8]	Knudsmark JK, Duke SO, Cedergreeen N. Potential ecological roles of artemisinin produced by Artemisia annua L[J]. J Chem Ecol, 2014, 40(2): 100-117.
[9]	Kiani BH, Kayani WK, Khayam AU, et al. Artemisinin and its derivatives: a promising cancer therapy[J]. Mol Biol Rep, 2020, 47(8): 6321-6336.
[10]	Wang Y, Wang Y, You F, et al. Novel use for old drugs: the emerging role of artemisinin and its derivatives in fibrosis[J]. Pharmacol Res, 2020, 157: 104829.
[11]	Jiang Y, Du H, Liu X, et al. Artemisinin alleviates atherosclerotic lesion by reducing macrophage inflammation via regulation of AMPK/NF-κB/NLRP3 inflammasomes pathway[J]. J Drug Target, 2020, 28(1): 70-79.
[12]	Jiang YY, Shui JC, Zhang BX, et al. The potential roles of artemisinin and its derivatives in the treatment of type 2 diabetes mellitus[J]. Front Pharmacol, 2020, 11: 585487.
[13]	Wang P, Liu T, Wang J, et al. Immunomodulative effects of artemisinin and its derivatives in the relative diseases[J]. Chin Trop Med, 2020, 20(2): 174-178. (in Chinese)
[13]	(王盼, 刘婷, 王静, 等. 青蒿素及其衍生物在相关疾病中的免疫调节作用[J]. 中国热带医学, 2020, 20(2): 174-178.)
[14]	Xie Y, Ni YW, Zhu ZY, et al. Research progress of effect of artemisinin family drugs on alleviating autoimmune diseases and their mechanisms[J]. Med Innov Chin, 2020, 17(7): 163-167. (in Chinese)
[14]	(谢宜, 倪宇雯, 朱泽宇, 等. 青蒿素类药物缓解自身免疫病及其机制的研究现状[J]. 中国医学创新, 2020, 17(7): 163-167.)
[15]	Li HJ, Wang W, Liang YS. Advances in research of dihydroartemisinin against parasitic diseases[J]. Chin J Schisto Control, 2011, 23(4): 460-464. (in Chinese)
[15]	(李洪军, 汪伟, 梁幼生. 双氢青蒿素抗寄生虫作用研究进展[J]. 中国血吸虫病防治杂志, 2011, 23(4): 460-464.)
[16]	Lu DM, Hu XS, Ma Y, et al. Studies on the effect of dihydroartemisinin on Leishmania donovani promastigotes in vitro[J]. J Pathog Biol, 1999, 12(1): 28-31. (in Chinese)
[16]	(芦殿梅, 胡孝素, 马莹, 等. 双氢青蒿素对杜氏利什曼原虫前鞭毛体作用体外实验研究[J]. 中国病原生物学杂志, 1999, 12(1): 28-31.)
[17]	Lu DM, Hu XS, Qiao ZD. Effect of dihydroartemisinin on Leishmania donovani promastigotes DNA analysed by flow cytometry[J]. Parasit Infect Dis, 1999, 7(3): 97-99. (in Chinese)
[17]	(芦殿梅, 胡孝素, 乔中东. 用流式细胞术分析双氢青蒿素对杜氏利什曼原虫DNA的作用[J]. 寄生虫病与感染性疾病, 1999, 7(3): 97-99.)
[18]	Cortes S, Albuquerque A, Cabral LI, et al. In vitro susceptibility of Leishmania infantum to artemisinin derivatives and selected trioxolanes[J]. Antimicrob Agents Chemother, 2015, 59(8): 5032-5035.
[19]	Esavand Heydari F, Ghaffarifar F, Soflaei S, et al. Comparison between in vitro effects of aqueous extract of artemisia seiberi and artemisinin on Leishmania major[J]. Jundishapur J Nat Pharm Prod, 2013, 8(2): 70-75.
[20]	Tian XF, Shen HE, Li J, et al. The effects of dihydroartemisinin on Giardia lamblia morphology and cell cycle in vitro[J]. Parasitol Res, 2010, 107(2): 369-375.
[21]	Dunay IR, Chan WC, Haynes RK, et al. Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model[J]. Antimicrob Agents Chemother, 2009, 53(10): 4450-4456.
[22]	Yin WD, Gao QC, Liu XD, et al. In vivo effect of dihydroartemisinin and azithromycin on the ultrastructure of Toxoplasma gondii tachyzoites[J]. Chin J Parasitol Parasit Dis, 2009, 27(4): 325-327. (in Chinese)
[22]	(尹卫东, 高全成, 刘向东, 等. 双氢青蒿素和阿奇霉素对小鼠体内弓形虫速殖子超微结构的影响[J]. 中国寄生虫学与寄生虫病杂志, 2009, 27(4): 325-327.)
[23]	Mazuz ML, Golenser J, Fish L, et al. Artemisone inhibits in vitro and in vivo propagation of Babesia bovis and B. bigemina parasites[J]. Exp Parasitol, 2013, 135(4): 690-694.
[24]	Xiao SH, Jian X, Tanner M, et al. Artemether, artesunate, praziquantel and tribendimidine administered singly at different dosages against Clonorchis sinensis: a comparative in vivo study[J]. Acta Trop, 2008, 106(1): 54-59.
[25]	Spicher M, Roethlisberger C, Lany C, et al. In vitro and in vivo treatments of Echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives[J]. Antimicrob Agents Chemother, 2008, 52(9): 3447-3450.
[26]	Keiser J, Shu-Hua X, Tanner M, et al. Artesunate and artemether are effective fasciolicides in the rat model and in vitro[J]. J Antimicrob Chemother, 2006, 57(6): 1139-1145.
[27]	Xiang F, Shi JQ, Yao KJ, et al. Research progress on anti-tumor effect of artemisinin[J]. Chin Clin Oncol, 2021, 26(5): 465-469. (in Chinese)
[27]	(相芳, 史坚强, 姚可娟, 等. 青蒿素类药物抗肿瘤作用的研究进展[J]. 临床肿瘤学杂志, 2021, 26(05): 465-469.)
[28]	Abd El-Kaream SA. Biochemical and biophysical study of chemopreventive and chemotherapeutic anti-tumor potential of some Egyptian plant extracts[J]. Biochem Biophys Rep, 2019, 18: 100637.
[29]	Verma S, Das P, Kumar VL. Chemoprevention by artesunate in a preclinical model of colorectal cancer involves down regulation of β-catenin, suppression of angiogenesis, cellular proliferation and induction of apoptosis[J]. Chem Biol Interact, 2017, 278: 84-91.
[30]	Greenshields AL, Shepherd TG, Hoskin DW. Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate[J]. Mol Carcinog, 2017, 56(1): 75-93.
[31]	Yao Y, Guo Q, Cao Y, et al. Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer[J]. J Exp Clin Cancer Res, 2018, 37(1): 282.
[32]	Guo B, Liu DX, Li LL, et al. Mechanism of artemisinin on p53 induced apoptosis of hepatocellular carcinoma cells[J]. Labeled Immunoassays Clin Med, 2017, 24(3): 314-316, 325. (in Chinese)
[32]	(郭彬, 刘殿星, 李雷雷, 等. 青蒿素调控p53蛋白诱导肝癌细胞凋亡的机制研究[J]. 标记免疫分析与临床, 2017, 24(3): 314-316, 325.)
[33]	Di TN, Cao HJ, Ge CL. Research status of artemisinin and its derivatives in reversing anti-tumor drug resistance[J]. Anti-Tumor Pharm, 2020, 10(6): 649-653, 663. (in Chinese)
[33]	(邸天男, 曹慧君, 葛春蕾. 青蒿素及其衍生物逆转抗肿瘤药物耐药性的研究现状[J]. 肿瘤药学, 2020, 10(6): 649-653, 663.)
[34]	D’Alessandro S, Scaccabarozzi D, Signorini L, et al. The use of antimalarial drugs against viral infection[J]. Microorganisms, 2020, 8(1): 85.
[35]	Yi XR, Yuan YC, Zhang XR, et al. The pilot study of anti-HBV effect of artesunate and its combination with bortezomib in HBV transgenic mice[J]. Pharmacol Clin Chin Mater Med, 2016, 32(2): 53-57. (in Chinese)
[35]	(易学瑞, 袁有成, 张欣蕊, 等. 青蒿琥酯及其与硼替佐米在HBV-Tg小鼠中抗病毒作用研究[J]. 中药药理与临床, 2016, 32(2): 53-57.)
[36]	Hutterer C, Niemann I, Milbradt J, et al. The broad-spectrum antiinfective drug artesunate interferes with the canonical nuclear factor kappa B (NF-κB) pathway by targeting RelA/p65[J]. Antivir Res, 2015, 124: 101-109.
[37]	Li M, Liu HJ, Cui XJ. Research progress in the use of artemisinin in the treatment of non-malarial diseases[J]. Chin Gen Pract, 2018, 21(12): 1508-1512. (in Chinese)
[37]	(李明, 刘洪江, 崔向军. 青蒿素类药物在非疟疾疾病中的研究进展[J]. 中国全科医学, 2018, 21(12): 1508-1512.)
[38]	Ni XY, Chen YT. In vitro study of the anti-Pneumocystis carinii effect of arteminsin derivatives[J]. Chin J Tuberc Respir Dis, 2001, 24(3): 164-167. (in Chinese)
[38]	(倪小毅, 陈雅棠. 青蒿素衍生物抗卡氏肺孢子虫体外作用的研究[J]. 中华结核和呼吸杂志, 2001, 24(3): 164-167.)
[39]	Ni XY, Chen YT, Wang J, et al. Sem observation of the anti-Pneumocystis carinii effect of arteminsin derivatives in vitro[J]. Chin J Parasit Dis Control, 2003, 16(4): 193-195. (in Chinese)
[39]	(倪小毅, 陈雅棠, 王健, 等. 青蒿素衍生物体外抗卡氏肺孢子虫作用的扫描电镜观察[J]. 中国寄生虫病防治杂志, 2003, 16(4): 193-195.)
[40]	Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant Cytomegalovirus infection after hematopoietic stem cell transplantation[J]. Clin Infect Dis, 2008, 46(9): 1455-1457.
[41]	Emadi F, Yassa N. Chemical composition of Iranian Artemisia annua L. essential oil and its antibacterial, antifungal and antioxidant effects[J]. Planta Med, 2009, 75.
[42]	Galal AM, Ross SA, Jacob M, et al. Antifungal activity of artemisinin derivatives[J]. J Nat Prod, 2005, 68(8): 1274-1276.
[43]	Gautam P, Upadhyay SK, Hassan W, et al. Transcriptomic and proteomic profile of Aspergillus fumigatus on exposure to artemisinin[J]. Mycopathologia, 2011, 172(5): 331-346.
[44]	Ebiamadon, Brisibe I, Sophia EA, et al. Controlling bruchid pests of stored cowpea seeds with dried leaves of Artemisia annua and two other common botanicals[J]. Afr J Biotechnol, 2011, 10(47): 9586-9592.
[45]	Duke SO, Vaughn KC, Croom EM Jr, et al. Artemisinin, a constituent of annual wormwood (Artemisia annua), is a selective phytotoxin[J]. Weed Sci, 1987, 35(4): 499-505.
[46]	Dayan FE, Hernández A, Allen SN, et al. Comparative phytotoxicity of artemisinin and several sesquiterpene analogues[J]. Phytochemistry, 1999, 50(4): 607-614.
[47]	Xiao SH, Guo J, Chollet J, et al. Effect of artemether on Schistosoma mansoni: dose-efficacy relationship, and changes in worm morphology and histopathology[J]. Chin J Parasitol Parasit Dis, 2004, 22(3): 148-153.
[48]	Xiao SH, Tanner M, Shen BG, et al. Effect of artemether on the tegument of adult Schistosoma haematobium recovered from mice[J]. Chin J Parasitol Parasit Dis, 2006, 24(6): 425-432.
[49]	Xiao SH, Sun J. Schistosoma hemozoin and its possible roles[J]. Int J Parasitol, 2017, 47(4): 171-183.
[50]	Sun J, Li C, Wang S. Organism-like formation of Schistosoma hemozoin and its function suggest a mechanism for anti-malarial action of artemisinin[J]. Sci Rep, 2016, 6: 34463.
[51]	Sun J, Hu W, Li C. Beyond heme detoxification: a role for hemozoin in iron transport in S. japonicum[J]. Parasitol Res, 2013, 112(8): 2983-2990.
[52]	Wang JG, Zhang CJ, Chia WN, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum[J]. Nat Commun, 2015, 6: 10111.
[53]	Wang JY, Wei W, Wang MD. Vitamin E and the antimalarial mechanism of artesunate[J]. Bull Acad Mil Med Sci, 1995, 19(4): 278-282. (in Chinese)
[53]	(王京燕, 魏文, 王明道. 维生素E与青蒿琥酯的抗疟机制[J]. 军事医学科学院院刊, 1995, 19(4): 278-282.)
[54]	Huang F, Tang LH. Advances in the study of iron chelating agents and antimalarial drugs[J]. Chin J Parasitol Parasit Dis, 2005, 23(4): 250-253. (in Chinese)
[54]	(黄芳, 汤林华. 铁螯合剂类抗疟药的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2005, 23(4): 250-253.)
[55]	Slezakova S, Ruda-Kucerova J. Anticancer activity of artemisinin and its derivatives[J]. Anticancer Res, 2017, 37(11): 5995-6003.
[56]	Han DM, Zhao YF, Li JL, et al. Progress of transferrin receptor in tumor research[J]. J Fujian Norm Univ Nat Sci Ed, 2018, 34(3): 110-106. (in Chinese)
[56]	(韩冬梅, 赵一帆, 李江林, 等. 转铁蛋白受体在肿瘤研究中的进展[J]. 福建师范大学学报(自然科学版), 2018, 34(3): 110-106.)
[57]	Shen Y, Li X, Dong D, et al. Transferrin receptor 1 in cancer: a new sight for cancer therapy[J]. Am J Cancer Res, 2018, 8(6): 916-931.
[58]	Torti SV, Manz DH, Paul BT, et al. Iron and cancer[J]. Annu Rev Nutr, 2018, 38(1): 97-125.

青蒿素类药物的广谱性及其潜在作用机制的探讨

A discussion on the broad-spectrum and potential mechanism of artemisinin and its derivatives

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 58

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李飞, 刘耀宝, 曹俊. 恶性疟原虫青蒿素耐药分子监测研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2025, 43(2): 260-268.
[2]	马悦, 赵保才, 周佳丽, 胡峻豪, 赵洪喜. miRNA在顶复门寄生虫感染中调控作用的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(6): 749-755.
[3]	蒋天哥, 曾文博, 李中秋, 张仪. 非编码RNA在利什曼病中的调控作用研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(1): 92-97.
[4]	杨博, 孙毅凡, 雷瑶, 程洋. 青蒿素及其衍生物治疗疟疾的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(3): 393-402.
[5]	叶升玉, 成依依, 李曼, 周红宁. 我国恶性疟原虫主要药物抗性研究[J]. 中国寄生虫学与寄生虫病杂志, 2020, 38(5): 631-636.
[6]	孙成松, 胡薇, 汪天平. 胞外囊泡介导血吸虫与宿主相互作用的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2020, 38(3): 378-382.
[7]	陈静, 刘耀宝, 唐凤, 陆凤, 唐建霞, 曹俊. 卵形疟原虫非洲分离株K13基因的多态性分析[J]. 中国寄生虫学与寄生虫病杂志, 2019, 37(2): 167-172.
[8]	牟畇珊, 李璐杰, 吴银娟, 李学荣. 疟原虫青蒿素耐药分子机制探索[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(6): 636-642.
[9]	郑文琪, 苏秀兰. 抗菌肽的抗疟原虫活性及作用机制的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(6): 643-647.
[10]	董莹, 孙艾明, 邓艳, 陈梦妮, 徐艳春, 毛祥华. 云南省恶性疟原虫氯喹及青蒿素抗性相关基因的联合突变分析[J]. 中国寄生虫学与寄生虫病杂志, 2017, 35(3): 202-208.
[11]	姚嘉青, 刘丛珊, 张皓冰. 寄生虫微管蛋白的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2017, 35(2): 180-184.
[12]	孙艾明1,2，董莹2*，陈梦妮2，徐艳春2，邓艳2，毛祥华2，王剑2. 云南省恶性疟原虫青蒿素耐药性相关基因 K13 kelch结构域序列多态性的分析[J]. 中国寄生虫学与寄生虫病杂志, 2016, 34(4): 8-339-345.
[13]	张逸龙，潘卫庆*. 恶性疟原虫对青蒿素产生抗性的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2015, 33(6): 5-418-424.
[14]	程慧芳，赵青，高娟，王锐利，张淑秋*. SYBR GreenⅠ法体外评价胆碱衍生物的抗恶性疟原虫活性[J]. 中国寄生虫学与寄生虫病杂志, 2015, 33(3): 8-196-199.
[15]	刘泽华，赵俊龙*. 抗菌肽抗寄生虫作用研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2014, 32(5): 11-377-379,384.